{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T07:52:57Z","timestamp":1785311577006,"version":"3.55.0"},"reference-count":16,"publisher":"Bentham Science Publishers Ltd.","issue":"2","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRP"],"published-print":{"date-parts":[[2020,8,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>To our knowledge, no previous study or literature review has been performed\nabout the effects of the extravasation of therapeutic radiopharmaceutical agents and its potential consequences,\nespecially regarding alpha-particle emitting radiopharmaceuticals.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> Even if Radium-223 dichloride is known to be a relatively safe drug to manage, despite the\ncorrectness of the procedures applied , unexpected delayed adverse effects can occur.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>In our vast experience, we rarely observed lymphedema, even after some time, at the site of administration.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Management of lymphedema caused by radiopharmaceuticals administration has been addressed\nthrough clinical examples. The sudden intervention allowed a fast remission of the signs and\nsymptoms complained by patients treated with Radium-223 dichloride.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions:<\/jats:title>\n<jats:p> The management of adverse effects after radiopharmaceuticals administration as in case\nof lymphedema onset, is extremely simple. These data confirm the safety of Radium-223 treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1874471012666190927115331","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T13:59:30Z","timestamp":1569592770000},"page":"159-163","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of Unusual Adverse Effects After Radium-223 Dichloride Administration"],"prefix":"10.2174","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3497-4236","authenticated-orcid":true,"given":"Viviana","family":"Frantellizzi","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Pontico","sequence":"additional","affiliation":[{"name":"Ph.D. Program in Morphogenesis and Tissue Engineering, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Pani","sequence":"additional","affiliation":[{"name":"Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan \u201cStatale\u201d, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pani","sequence":"additional","affiliation":[{"name":"Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"De Vincentis","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/1060028014558153","volume":"49(1)","author":"Laroche, M.L.","year":"2015","unstructured":"Laroche, M.L.; Quelven,I.; Maz\u00e8re,J.; Merle, L. Adverse reactions to radiopharmaceuticals in France: Analysis of the national phar-macovigilance database. Ann. Pharmacother. 2015,49(1),39-47. http:\/\/dx.doi.org\/10.1177\/1060028014558153 PMID: 25366341","journal-title":"Ann.Pharmacother"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"340.e7","DOI":"10.1016\/j.urolonc.2018.03.022","volume":"36(7)","author":"Sciarra,A.","year":"2018","unstructured":"Sciarra,A.; Gentilucci,A.; Salciccia,S.; Von Heland,M.; Ricciuti, G.P.; Marzio,V.; Pierella,F.; Musio,D.; Tombolini,V.; Frantel-lizzi,V.; Pasquini,M.; Maraone,A.; Guandalini,A.; Maggi, M. Psychological and functional effect of different primary treatments for prostate cancer: A comparative prospective analysis. Urol. On-col. 2018,36(7),340.e7-340.e21. http:\/\/dx.doi.org\/10.1016\/j.urolonc.2018.03.022 PMID: 29706458","journal-title":"Urol.On-col"},{"key":"ref=3","author":"Ricci,M.","unstructured":"Ricci,M.; Frantellizzi,V.; Bulzonetti,N.; De Vincentis, G. Re-versibility of castration resistance status after Radium-223 dichlo-ride treatment: Clinical evidence and Review of the literature. Int, J. Radiat. Biol. 2018,1-29. PMID: 30557063","journal-title":"Int, J.Radiat..Biol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00259-017-3756-7","volume":"44(10)","author":"Du,Y.","year":"2017","unstructured":"Du,Y.; Carrio,I.; De Vincentis,G.; Fanti,S.; Ilhan,H.; Mommsen,C.; Nitzsche,E.; Sundram,F.; Vogel,W.; Oyen,W.; Lewington, V. Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. Eur, J. Nucl. Med. Mol. Imag-ing. 2017,44(10),1671-1678. http:\/\/dx.doi.org\/10.1007\/s00259-017-3756-7 PMID: 28631036","journal-title":"Eur, J.Nucl.Med.Mol.Imag-ing"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369(3)","author":"Parker,C.","year":"2013","unstructured":"Parker,C.; Nilsson,S.; Heinrich,D.; Helle, S.I.; O\u2019Sullivan, J.M.; Foss\u00e5, S.D.; Chodacki,A.; Wiechno,P.; Logue,J.; Seke,M.; Widmark,A.; Johannessen, D.C.; Hoskin,P.; Bottomley,D.; James, N.D.; Solberg,A.; Syndikus,I.; Kliment,J.; Wedel,S.; Boehmer,S.; Dall\u2019Oglio,M.; Franz\u00e9n,L.; Coleman,R.; Vogel-zang, N.J.; O\u2019Bryan-Tear, C.G.; Staudacher,K.; Garcia-Vargas,J.; Shan,M.; Bruland, \u00d8.S.; Sartor, O. ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate can-cer, N. Engl, J. Med. 2013,369(3),213-223. http:\/\/dx.doi.org\/10.1056\/NEJMoa1213755 PMID: 23863050","journal-title":"Alpha emitter radium-223 and survival in metastatic prostate can-cer, N.Engl, J.Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.2217\/fon-2018-0318","volume":"14(27)","author":"De,Vincentis,G.;,Monari,F.;,Baldari,S.;,Salgarello,M.;,Frantel-lizzi,V.;,Salvi,E.;,Reale,L.;,Napolitano,S.;,Conti,G.;,Cortesi.","year":"2018","unstructured":"De Vincentis,G.; Monari,F.; Baldari,S.; Salgarello,M.; Frantel-lizzi,V.; Salvi,E.; Reale,L.; Napolitano,S.; Conti,G.; Cortesi, E. Narrative medicine in metastatic prostate cancer reveals ways to improve patient awareness and quality of care. Future Oncol. 2018,14(27),2821-2832. http:\/\/dx.doi.org\/10.2217\/fon-2018-0318 PMID: 29905090","journal-title":"Future Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12149-017-1228-6","volume":"32(2)","author":"Frantellizzi,V.","year":"2018","unstructured":"Frantellizzi,V.; Farcomeni,A.; Follacchio, G.A.; Pacilio,M.; Pellegrini,R.; Pani,R.; De Vincentis, G. A 3-variable prognostic score (3-PS)  for overall survival prediction in metastatic castration-resistant prostate cancer treated with 223Radium-dichloride. Ann. Nucl. Med. 2018,32(2),142-148. http:\/\/dx.doi.org\/10.1007\/s12149-017-1228-6 PMID: 29285670","journal-title":"Ann.Nucl.Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40520-017-0826-4","volume":"30(6)","author":"De,Vincentis,G.;,Follacchio.","year":"2018","unstructured":"De Vincentis,G.; Follacchio, G.A.; Frante-llizzi,V.; Prelaj,A.; Farcomeni,A.; Giuli,A.; Bianco,V.; Tomao, S. 223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with ex-isting literature. Aging Clin. Exp. Res. 2018,30(6),677-680. http:\/\/dx.doi.org\/10.1007\/s40520-017-0826-4 PMID: 28856577","journal-title":"Aging Clin.Exp.Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10549-014-2939-1","volume":"145(2)","author":"Coleman,R.","year":"2014","unstructured":"Coleman,R.; Aksnes, A-K.; Nau-me,B.; Garcia,C.; Jerusalem,G.; Piccart,M.; Vobecky,N.; Thuresson,M.; Flamen, P. A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res. Treat. 2014,145(2),411-418. http:\/\/dx.doi.org\/10.1007\/s10549-014-2939-1 PMID: 24728613","journal-title":"Breast Cancer Res.Treat"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.2967\/jnumed.117.194092","volume":"58(12)","author":"Kennedy-Dixon, T.G.","year":"2017","unstructured":"Kennedy-Dixon, T.G.; Gossell-W illiams,M.; Cooper,M.; Trabelsi,M.; Vinjamuri, S. Evaluation of radiopharmaceutical adverse reac-tion reports to the british nuclear medicine society from 2007 to 2016. J. Nucl. Med. 2017,58(12),2010-2012. http:\/\/dx.doi.org\/10.2967\/jnumed.117.194092 PMID: 28522742","journal-title":"J.Nucl.Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s00259-012-2120-1","volume":"39(8)","author":"Salvatori,M.","year":"2012","unstructured":"Salvatori,M.; Treglia,G.; Mores, N. Further considerations on adverse reactions to radiopharmaceuticals. Eur, J. Nucl. Med. Mol. Imaging. 2012,39(8),1360-1362. http:\/\/dx.doi.org\/10.1007\/s00259-012-2120-1 PMID: 22526962","journal-title":"Eur, J.Nucl.Med.Mol.Imaging"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s00259-017-3675-7","volume":"44(7)","author":"van der Pol,J.","year":"2017","unstructured":"van der Pol,J.; V\u00f6\u00f6, S.; Bucerius,J.; Mottaghy, F.M. Conse-quences of radiopharmaceutical extravasation and therapeutic in-terventions: a systematic review. Eur, J. Nucl. Med. Mol. Imaging. 2017,44(7),1234-1243. http:\/\/dx.doi.org\/10.1007\/s00259-017-3675-7 PMID: 28303300","journal-title":"Eur, J.Nucl.Med.Mol.Imaging"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/s00259-012-2071-6","volume":"39(5)","author":"Hesse,B.","year":"2012","unstructured":"Hesse,B.; Vinberg,N.; Berthelsen, A.K.; Ballinger, J.R. Adverse events in nuclear medicine-cause for concern? Eur, J. Nucl. Med. Mol. Imaging. 2012,39(5),782-785. http:\/\/dx.doi.org\/10.1007\/s00259-012-2071-6 PMID: 22310855","journal-title":"Nucl.Med.Mol.Imaging"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s00259-007-0372-y","volume":"34(4)","author":"Tennvall,J.","year":"2007","unstructured":"Tennvall,J.; Fischer,M.; Bischof Delaloye,A.; Bombardieri,E.; Bodei,L.; Giammarile,F.; Lassmann,M.; Oyen,W.; Brans, B. Therapy committee, EANM oncology committee, EANM dosime-try committee, EANM. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibri-tumomab tiuxetan (Zevalin) . Eur, J. Nucl. Med. Mol. Imaging. 2007,34(4),616-622. http:\/\/dx.doi.org\/10.1007\/s00259-007-0372-y PMID: 17323056","journal-title":"EANMprocedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibri-tumomab tiuxetan (Zevalin) .Eur, J.Nucl.Med.Mol.Imaging"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/pon.3201","volume":"22(7)","author":"Fu, M.R.","year":"2013","unstructured":"Fu, M.R.; Ridner, S.H.; Hu, S.H.; Stewart, B.R.; Cormier, J.N.; Armer, J.M. Psychosocial impact of lymphedema: A systematic re-view of literature from 2004 to 2011. Psychooncology. 2013,22(7),1466-1484. http:\/\/dx.doi.org\/10.1002\/pon.3201 PMID: 23044512","journal-title":"Psychooncology"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1547-5069.2008.00248.x","volume":"40(4)","author":"Fu, M.R.","year":"2008","unstructured":"Fu, M.R.; Axelrod,D.; Haber, J. Breast-cancer-related lymphe-dema: information, symptoms, and risk-reduction behaviors, J. Nurs. Scholarsh. 2008,40(4),341-348. http:\/\/dx.doi.org\/10.1111\/j.1547-5069.2008.00248.x PMID: 19094149","journal-title":"Nurs.Scholarsh"}],"container-title":["Current Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/175177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T14:32:27Z","timestamp":1605018747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/175177\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874471012666190927115331","relation":{},"ISSN":["1874-4710"],"issn-type":[{"value":"1874-4710","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}